# Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

> **NCT05759520** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fosun Adgenvax Biopharmaceutical Co.,Ltd.** · enrollment: 1800 (estimated)

## Conditions studied

- Streptococcus Pneumoniae Infection

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
- **BIOLOGICAL:** Prevenar 13

## Key facts

- **NCT ID:** NCT05759520
- **Lead sponsor:** Fosun Adgenvax Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-04
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759520, "Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05759520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*